Naratriptan Orifarm (Naratriptan)

Naratriptan is a selective serotonin 5‑HT1B/1D receptor agonist used in the acute migraine treatment pathway.

• Migraine attack: provides rapid relief of headache pain and associated symptoms.
• Migraine with aura: helps terminate the headache phase after aura subsides.
• Migraine‑related nausea: reduces nausea and vomiting associated with an attack.
• Migraine photophobia: lessens sensitivity to light during an attack.
• Migraine phonophobia: diminishes sound sensitivity accompanying the headache.

• Naratriptan acts as a selective agonist at serotonin 5‑HT1B and 5‑HT1D receptors located on cranial blood vessels and trigeminal nerve endings. Activation of 5‑HT1B receptors induces vasoconstriction of dilated intracranial arteries, while stimulation of 5‑HT1D receptors inhibits release of pro‑inflammatory neuropeptides such as CGRP. Together these actions abort the neurovascular cascade that underlies migraine pain and thereby provides clinical relief.

Common and serious adverse reactions have been reported with naratriptan use.

Common Side Effects

• Tingling or numbness in fingers or toes
• Warmth or flushing sensation
• Dizziness or light‑headedness
• Dry mouth
• Nausea
• Fatigue

Serious or Rare Side Effects

• Chest pain or tightness suggestive of coronary spasm
• Severe allergic reaction including rash, swelling, or anaphylaxis
• Serotonin syndrome manifested by agitation, fever, or muscle rigidity
• Severe hypertension
• Vision disturbances

When prescribing naratriptan, clinicians should consider several precautionary measures to ensure safe use.

• Cardiovascular disease: avoid in patients with coronary artery disease, uncontrolled hypertension, or history of myocardial infarction.
• Age considerations: use with caution in elderly patients due to increased sensitivity to vasoconstrictive effects.
• Concomitant serotonergic drugs: monitor for signs of serotonin syndrome when combined with SSRIs, SNRIs, or MAO inhibitors.
• Hepatic impairment: dose adjustment may be required in moderate to severe liver dysfunction.
• Pregnancy and lactation: safety has not been established; prescribe only if potential benefit justifies the risk.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Naratriptan may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Ergot alkaloids: concurrent use can cause excessive vasoconstriction and increase risk of serious cardiovascular events.
• Monoamine oxidase inhibitors (MAOIs): combined therapy may precipitate severe hypertension or serotonin syndrome.
• Other triptans: using more than one triptan within 24 hours can raise the risk of vasospastic complications.

Moderate Interactions (Monitor Closely)

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): may increase serotonin levels, requiring observation for serotonin syndrome.
• Antihypertensive agents: naratriptan’s vasoconstrictive action may diminish the blood‑pressure‑lowering effect.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise naratriptan plasma concentrations, potentially intensifying adverse effects.